8 Jun 2011

BioMedical Research Market Report


PWRM, Power 3 Medical Products Inc., (OTCBB: PWRM.OB) is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer’s Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the PWRM’s NuroPro AD biomarkers and blood test for Alzheimer’s disease. The four studies to be presented involve a total of 154 Alzheimer’s disease patients and 91 Parkinson’s disease patients, as well as 210 age-matched normal control individuals and 173 disease control individuals. NexMed, Inc. (Nasdaq: NEXMD), a specialty CRO with a pipeline of product candidates based on the NexACT technology, recently announced that the Company will present data at the International Liver Cancer Association (ILCA) Fourth Annual Conference from September 10-12, 2010 in Montreal, Canada. The presentation, entitled, “PrevOnco® Exhibits In Vitro Cytolytic Activity, Prolongs Survival in Kidney Cancer and Leukemia Models and Reduces Tumor Growth Rates Alone and in Concert in a Liver Cancer Model,” is scheduled to be presented by Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, on Saturday, September 11, 2010 from 2:30 - 4:30 p.M. NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide.Sangamo BioSciences, Inc. (Nasdaq:SGMO) announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. The ZFN approach enables the permanent disruption of the CCR5 gene, which encodes an important receptor for HIV infection, in all the cell types comprising the immune system that develop from hematopoietic stem cells (HSCs), and is the basis for a promising therapeutic strategy for the treatment of HIV/AIDS. Sangamo has two ongoing Phase 1 clinical trials to evaluate the safety and clinical efficacy of this approach in CD4+ T-cells. SGMO engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs can be engineered to make ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off; and ZFP nucleases, proteins that enable to modify DNA sequences in various ways. 

No comments:

Post a comment